Skip to main content
OUR COMPANY
Mission & strategy
Executive Insights
Contact us
Compliance
OUR SCIENCE
Pipeline
Tovorafenib
DAY301
Emi-Le
Clinical trials
Expanded access
Publications & posters
Investigator-sponsored research
OUR MEDICINE
OJEMDA™ (tovorafenib)
PATIENTS
Overview
Patient stories
Our advocacy team
Resources
CAREERS
Overview
Open positions
Benefits
Inclusion & belonging
Culture
MEDIA & INVESTORS
Overview
News & events
Stock information
Financial information
Corporate governance
Investor resources
×
You are now leaving the Day One Biopharmaceuticals Corporate Website
You will now be redirected to the requested website. Please confirm that you want to proceed.
Yes
No
Day One Biopharmaceuticals in now a part of Servier Group |
Read the press release
CLOSE